Andreessen Horowitz
Listed as “Asimov”
- First observed:
- 29 Oct 2026
- Investment announced:
- Date not recorded
Asimov develops tools for genetic design and cell engineering.
Its suite combines cells, genes, and software for genetic design. The company also offers engineered host cells for therapeutic applications.
Bio + Health
Category source ↗Checked
Some source history is available; coverage remains limited.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
Listed as “Asimov”
No dated funding or investment events are recorded yet. Initial portfolio listings establish the starting baseline and earn no points.